Replies to post #143305 on Biotech Values

[DewDiligence]

Tough day for ThromboGenics and BioInvent—in addition to the failure and program termination of TB-402 (#msg-76294033), former partner Roche dumped TB-403, a cancer drug targeting PIGF:

http://finance.yahoo.com/news/thrombogenics-bioinvent-regain-full-rights-053200538.html

[mcbio]

TB-402 (unsurprisingly) bombs in head-to-head vs Xarelto; program terminated

BioInvent also has a human antibody in BI-204 targeting the oxidised form of the low-density lipoprotein apoB100 for atherosclerosis. The drug is partnered with Genentech and Phase 2a results are due this quarter. Any comments on this drug (http://www.bioinvent.com/products/pipeline/bi-204 )?

If Yahoo is anywhere near accurate (always a gamble), market cap for BioInvent is just ~$55M. I know they've had some setbacks of late, but they have BI-204, along with BI-505, which targets ICAM-1 (CD54) for MM in Phase 1. That drug also has Phase 1 results due this quarter. They also have a few other technology partnerships with the likes of Bayer, Daiichi Sankyo, and a few others. At first blush, seems like an interesting little company, particularly if market cap really is ~$55M.